Sandeep Seth to exit Pfizer as Senior Director - Compliance

Published On 2025-04-02 06:00 GMT   |   Update On 2025-04-02 07:25 GMT

MumbaiPfizer has announced that Sandeep Seth, Senior Director - Compliance, has tendered his resignation from the services of the Company.

His departure will be effective from the close of business hours on May 13, 2025, as he plans to pursue opportunities outside Pfizer Limited.

Following his resignation, Sandeep Seth shall accordingly cease to be a Senior Management Personnel at Pfizer, marking the end of his tenure with the pharmaceutical giant.

Sandeep Seth joined Pfizer in 2016 as Director of Corporate Compliance and steadily climbed the ranks within the company. In 2022, he was promoted to Senior Director and Cluster Compliance Lead for South Asia and Turkey.

With over 20 years of experience in Compliance, Regulatory Affairs, Legal, and Operations, Seth has been a significant contributor to the industry. His career spans reputed multinational corporations, including MSD Pharmaceuticals, Max Bupa, and MetLife India Insurance Co. He has comprehensive knowledge & exposure of Ethics & Compliance policies, practices and processes.

Pfizer is yet to announce a successor for his role.

Pfizer was founded more than 170 years ago. 

Pfizer Limited was listed on the Bombay stock exchange in 1966. Today, the company has over one lakh shareholders in India. With annual sales of over Rs. 2,000 crores, it is the fourth largest multinational pharmaceutical company in India. The Company has a portfolio of over 150 products across 15 therapeutic areas.

Its top brands include Prevenar 13, Corex – DX, Dolonex, Enbrel, Becosules and Folvite among others. In addition to its commercial operations, Pfizer Limited also operates a state-of-the-art, award-winning manufacturing facility in Goa that produces more than a billion tablets annually.

The Company specialises with expert therapy in 4 business categories - Vaccines, Hospitals, Internal Medicine and Inflammation and Immunology.

Read also: USFDA approves Pfizer Adcetris combination regimen for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News